Literature DB >> 30158053

CELF1 contributes to aberrant alternative splicing patterns in the type 1 diabetic heart.

KarryAnne Belanger1, Curtis A Nutter1, Jin Li2, Sadia Tasnim1, Peiru Liu3, Peng Yu4, Muge N Kuyumcu-Martinez5.   

Abstract

Dysregulated alternative splicing (AS) that contributes to diabetes pathogenesis has been identified, but little is known about the RNA binding proteins (RBPs) involved. We have previously found that the RBP CELF1 is upregulated in the diabetic heart; however, it is unclear if CELF1 contributes to diabetes-induced AS changes. Utilizing genome wide approaches, we identified extensive changes in AS patterns in Type 1 diabetic (T1D) mouse hearts. We discovered that many aberrantly spliced genes in T1D hearts have CELF1 binding sites. CELF1-regulated AS affects key genes within signaling pathways relevant to diabetes pathogenesis. Disruption of CELF1 binding sites impairs AS regulation by CELF1. In sum, our results indicate that CELF1 target RNAs are aberrantly spliced in the T1D heart leading to abnormal gene expression. These discoveries pave the way for targeting RBPs and their RNA networks as novel therapies for cardiac complications of diabetes.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alternative splicing; CELF1; Diabetic heart; RNA binding proteins

Mesh:

Substances:

Year:  2018        PMID: 30158053      PMCID: PMC6142808          DOI: 10.1016/j.bbrc.2018.08.126

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  38 in total

1.  Cardiovascular complications of diabetes.

Authors:  S Caprio; S Wong; K G Alberti; G King
Journal:  Diabetologia       Date:  1997-10       Impact factor: 10.122

2.  STAR: ultrafast universal RNA-seq aligner.

Authors:  Alexander Dobin; Carrie A Davis; Felix Schlesinger; Jorg Drenkow; Chris Zaleski; Sonali Jha; Philippe Batut; Mark Chaisson; Thomas R Gingeras
Journal:  Bioinformatics       Date:  2012-10-25       Impact factor: 6.937

3.  Analysis and design of RNA sequencing experiments for identifying isoform regulation.

Authors:  Yarden Katz; Eric T Wang; Edoardo M Airoldi; Christopher B Burge
Journal:  Nat Methods       Date:  2010-11-07       Impact factor: 28.547

4.  ABLIM1 splicing is abnormal in skeletal muscle of patients with DM1 and regulated by MBNL, CELF and PTBP1.

Authors:  Natsumi Ohsawa; Michinori Koebis; Hiroaki Mitsuhashi; Ichizo Nishino; Shoichi Ishiura
Journal:  Genes Cells       Date:  2014-11-18       Impact factor: 1.891

5.  Developmentally regulated alternative splicing is perturbed in type 1 diabetic skeletal muscle.

Authors:  Curtis A Nutter; Elizabeth Jaworski; Sunil K Verma; Yareli Perez-Carrasco; Muge N Kuyumcu-Martinez
Journal:  Muscle Nerve       Date:  2017-04-17       Impact factor: 3.217

6.  A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart.

Authors:  Auinash Kalsotra; Xinshu Xiao; Amanda J Ward; John C Castle; Jason M Johnson; Christopher B Burge; Thomas A Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

Review 7.  Diabetic cardiomyopathy revisited.

Authors:  Sihem Boudina; E Dale Abel
Journal:  Circulation       Date:  2007-06-26       Impact factor: 29.690

8.  Differential expression analysis for sequence count data.

Authors:  Simon Anders; Wolfgang Huber
Journal:  Genome Biol       Date:  2010-10-27       Impact factor: 13.583

9.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

10.  Ancient antagonism between CELF and RBFOX families tunes mRNA splicing outcomes.

Authors:  Matthew R Gazzara; Michael J Mallory; Renat Roytenberg; John P Lindberg; Anupama Jha; Kristen W Lynch; Yoseph Barash
Journal:  Genome Res       Date:  2017-05-16       Impact factor: 9.043

View more
  7 in total

1.  Alternative Splicing of the Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT) Is Regulated by RBFOX2 in Lymphoid Malignancies.

Authors:  Amy M Cooper; Curtis A Nutter; Muge N Kuyumcu-Martinez; Casey W Wright
Journal:  Mol Cell Biol       Date:  2022-04-11       Impact factor: 5.069

Review 2.  Advances in the study of RNA-binding proteins in diabetic complications.

Authors:  Xinyue Chen; Jiaqiang Wu; Zhangwang Li; Jiashu Han; Panpan Xia; Yunfeng Shen; Jianyong Ma; Xiao Liu; Jing Zhang; Peng Yu
Journal:  Mol Metab       Date:  2022-05-18       Impact factor: 8.568

3.  A developmentally regulated spliced variant of PTBP1 is upregulated in type 1 diabetic hearts.

Authors:  KarryAnne Belanger; Curtis A Nutter; Jin Li; Peng Yu; Muge N Kuyumcu-Martinez
Journal:  Biochem Biophys Res Commun       Date:  2018-12-26       Impact factor: 3.575

4.  miRDRN-miRNA disease regulatory network: a tool for exploring disease and tissue-specific microRNA regulatory networks.

Authors:  Hsueh-Chuan Liu; Yi-Shian Peng; Hoong-Chien Lee
Journal:  PeerJ       Date:  2019-08-06       Impact factor: 2.984

5.  RBFOX2 is critical for maintaining alternative polyadenylation patterns and mitochondrial health in rat myoblasts.

Authors:  Jun Cao; Sunil K Verma; Elizabeth Jaworski; Stephanie Mohan; Chloe K Nagasawa; Kempaiah Rayavara; Amanda Sooter; Sierra N Miller; Richard J Holcomb; Mason J Powell; Ping Ji; Nathan D Elrod; Eda Yildirim; Eric J Wagner; Vsevolod Popov; Nisha J Garg; Andrew L Routh; Muge N Kuyumcu-Martinez
Journal:  Cell Rep       Date:  2021-11-02       Impact factor: 9.423

6.  CELF1 promotes matrix metalloproteinases gene expression at transcriptional level in lens epithelial cells.

Authors:  Jun Xiao; Xin Tian; Siyan Jin; Yanhui He; Meijiao Song; He Zou
Journal:  BMC Ophthalmol       Date:  2022-03-14       Impact factor: 2.209

7.  RBPTD: a database of cancer-related RNA-binding proteins in humans.

Authors:  Kun Li; Zhi-Wei Guo; Xiang-Ming Zhai; Xue-Xi Yang; Ying-Song Wu; Tian-Cai Liu
Journal:  Database (Oxford)       Date:  2020-01-01       Impact factor: 3.451

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.